U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H22ClN3O2
Molecular Weight 323.818
Optical Activity ( + / - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RENZAPRIDE

SMILES

COC1=CC(N)=C(Cl)C=C1C(=O)N[C@@H]2CC[N@@]3CCC[C@H]2C3

InChI

InChIKey=GZSKEXSLDPEFPT-LNUXAPHWSA-N
InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10?,14-/m1/s1

HIDE SMILES / InChI

Description

Renzapride (BRL-24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist. This compound has a stimulatory effect on gastrointestinal motility and transit. Renzapride has been evaluated for use in treatment of irritable bowel syndrome (IBS). Data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. Phase III clinical trials investigated if this drug could help alleviate the symptoms associated with this type of IBS. However, one phase III study has been terminated due to inefficient efficacy (compared to placebo).

Approval Year

PubMed